当前位置: 首页 > 详情页

The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Neurosurgery, Huashan Hospital, Fudan University, 12# Mid Wulumuqi Road, Shanghai, China [2]Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, 6# Tiantanxili, Beijing, China [3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 6# Tiantanxili, Beijing, China [4]Department of Neurosurgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China [5]Neurosurgical Immunology Laboratory, Neurosurgical Institute of Fudan University, Shanghai, China [6]Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China [7]Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China [8]Department of Pathology, Basic Medical Science, Fudan University, Shanghai, China [9]Evidence Based Medicine Center, Fudan University, Shanghai, China [10]Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA [11]Department of Neuro?Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
出处:
ISSN:

关键词: Glioma Extent of resection Prognostic value Molecular subgroup

摘要:
Purpose Maximal surgical resection is associated with survival benefit in the majority of studies in adult diffuse glioma. This study aims to characterize the prognostic value of surgical resection in molecular subgroups of diffuse glioma. Methods 1178 patients with diffuse glioma from our centers and 422 from TCGA dataset were collected. The Kaplan-Meier analysis and multivariable Cox regression models were conducted to identify the prognostic value of surgical resection through different histological and molecular stratifications. Results Firstly, we confirmed progression-free survival (PFS) benefit associated with gross total resection (GTR) over sub-total resection (STR) in lower-grade glioma (HR 1.49; 95% CI 1.17-1.90; P = 0.001). Intriguingly however, we were unable to detect a significant PFS or overall survival (OS) benefit in oligodendroglioma (N = 397; HR 1.36; 95% CI 0.86-2.14; P = 0.19 and HR 1.05; 95% CI 0.55-1.99; P = 0.89, respectively). Secondly, when analyzed in molecular subgroups, we were similarly unable to detect a significant PFS or OS benefit in IDH MT/codel subgroup (N = 269; HR 1.47; 95% CI 0.92-2.34; P = 0.11 and HR 1.54; 95% CI 0.78-3.05; P = 0.21, respectively), oligodendroglioma with IDH MT/codel subgroup (N=233; HR 1.33; 95% CI 0.79-2.21; P = 0.28 and HR 1.16; 95% CI 0.53-2.54; P = 0.70, respectively) or other relevant subgroups. TCGA validation also showed a significant survival benefit in astrocytoma rather than oligodendroglioma. Exploratory RNAseq analysis displayed that fewer cell proliferation-related gene expression features were specific to oligodendroglioma. Conclusion These results suggest that the benefit of maximal surgery may be attenuated in patients within oligodendroglioma relevant subgroups because of the chemosensitive and indolent nature. The aggressive surgery accompanying with risk of neurologic morbidity may be unnecessary for these patients given the lack of survival benefit with gross total resection.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学 3 区 肿瘤学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 临床神经病学 3 区 肿瘤学
JCR分区:
出版当年[2016]版:
Q2 CLINICAL NEUROLOGY Q3 ONCOLOGY
最新[2023]版:
Q2 CLINICAL NEUROLOGY Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Department of Neurosurgery, Huashan Hospital, Fudan University, 12# Mid Wulumuqi Road, Shanghai, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Neurosurgery, Huashan Hospital, Fudan University, 12# Mid Wulumuqi Road, Shanghai, China [2]Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, 6# Tiantanxili, Beijing, China [3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 6# Tiantanxili, Beijing, China [5]Neurosurgical Immunology Laboratory, Neurosurgical Institute of Fudan University, Shanghai, China [11]Department of Neuro?Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院